Therapeutically robust correction, in vitro, of the most common cystic fibrosis mutation

(University of Alabama at Birmingham) In experiments with isolated cystic fibrosis lung cells, researchers have partially restored the lost function of those cells to therapeutic levels. The work is proof-of-concept for using a yeast genetic model to find therapeutic targets, in this case for people with the most common cystic fibrosis mutation, called deltaF508-CFTR.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news